Skip to content

Pharvaris

US · PHVS #2729 by market cap Listed 2021
31.28 -0.38 -1.20%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 30.86 -2.53%
After-hours 31.28 0.00%
Overnight 31.20 -1.45%
38.8627.7431.282026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on PHVS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +7.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 3.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -65.2% Better than 7%
Return on invested capital -65.0% Better than 4%
Momentum B-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -13.8% Better than 42%
6-month return 5.4% Better than 65%
12-month return (ex latest month) 23.6% Better than 63%
Distance below 52-week high 27.7% Better than 46%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.1x Better than 93%
Debt to assets 0.3% Better than 97%
Interest coverage -4,696.5x Better than 1%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 99.6% Better than 83%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.24%
1M +1.23%
3M -14.04%
6M +6.21%
YTD +12.72%
1Y +29.26%
3Y +105.79%
5Y +100.90%

Key statistics

Price & volume

Prev close
31.66
Open
31.41
Day range
30.43 - 31.99
Avg price
31.36
Volume
464.01K
Turnover
14.55M
Amplitude
4.93%
52-week range
23.15 - 43.25

Valuation

P/E
-9.60
P/E (TTM)
-10.60
P/B
7.62
EPS
-3.26
Net profit
-230.57M
Net assets
290.60M

Share structure

Market cap
2.21B
Float cap
1.72B
Shares out
70.79M
Float shares
55.10M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-02-05
52-week range 40% of range
23.15 43.25

27.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+3.29M net over the window

Short interest

Shares short
2.54M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Pharvaris (PHVS)?

Pharvaris last traded at 31.28. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Pharvaris's market cap?

About 2.21B.

What is the P/E ratio of Pharvaris?

The trailing twelve-month P/E is -10.60. The Valuation tab shows it against the stock's own five-year range.

Does Pharvaris pay a dividend?

Pharvaris does not currently pay a regular dividend.

Is Pharvaris a buy according to analysts?

The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 62.45, which implies 99.6% upside from the current price. This is not investment advice.

What is Pharvaris's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Pharvaris a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:01:10 · For reference only, not investment advice and not tailored to your situation.

Pharvaris discussion 0 comments

Add a comment